Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Operating Expenses (2016 - 2021)

GT Biopharma (GTBP) has disclosed Operating Expenses for 12 consecutive years, with $18.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Operating Expenses rose 729.67% to $18.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was $57.5 million, a 908.93% increase, with the full-year FY2025 number at $6.8 million, up 49.93% from a year prior.
  • Operating Expenses was $18.2 million for Q4 2021 at GT Biopharma, up from $6.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $126.9 million in Q3 2017 to a low of -$230.9 million in Q4 2019.
  • A 5-year average of -$652842.1 and a median of $4.4 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 4914.07% in 2017, then crashed 234.71% in 2020.
  • GT Biopharma's Operating Expenses stood at $5.9 million in 2017, then fell by 14.53% to $5.0 million in 2018, then crashed by 4686.32% to -$230.9 million in 2019, then skyrocketed by 100.95% to $2.2 million in 2020, then surged by 729.67% to $18.2 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Operating Expenses are $18.2 million (Q4 2021), $6.0 million (Q3 2021), and $4.4 million (Q2 2021).